Full Name
Prof Lawrence Ho
Designation
Director, Centre for Innovation in Healthcare, NUHS
Bio
Professor Ho is Professor of Medicine, National University of Singapore; Senior Consultant, National University Hospital; and Director, Centre for Innovation in Healthcare, National University Health System. Besides being an accomplished endoscopist, he is an international key opinion leader, being made Fellow of Japan Gastroenterological Endoscopy Society, to recognize his significant contributions to the field of gastrointestinal endoscopy.

Experienced in spearheading collaboration between researchers in Asia, he was the founding Chairman of the Asian EUS Group. He also co-chairs Gut & Obesity in Asia (“Go Asia”) Workgroup, and the Asian Barrett’s Consortium.

A proven clinician innovator and experienced entrepreneur, he co-invented the Master and Slave Transluminal Endoscopic Robot (MASTER), which has since been spun-off into the start-up, Endomaster. He also founded two other start-up companies, Endofotonics, a molecular AI based realtime diagnostic system, and Endopil, an ingestible weight loss balloon capsule. He received the Singapore President’s Technology Award in 2012.

The Ministry of Heath Singapore awarded him the Distinguished Senior Clinician award in 2018. He was conferred the Public Administration Medal (Bronze) in 2017. He has published more than 270 peer-reviewed papers (H index Google Scholar, 61), and held 6 US-granted patents in medtech products.
Topic
Innovation & Entrepreneurship in Medicine. Can we leverage on innovation to change practice?
Abstract
Patients are living longer, healthier, and more productive lives thanks to the innovative drugs. Care is becoming more consistent, and in some cases, faster too, thanks to the medtech innovations. Health gains and savings in the healthcare system have happened thanks to breakthrough innovations such as vaccination. Despite these benefits, healthcare innovations will have no impact if they cannot be deployed and sustained at scale. To have innovations adopted at scale, clinicians will need to partner entrepreneurs/industry who will provide the necessary culture and skillset to drive the innovations at pace. These entrepreneurs and industry partners will also help to overcome many barriers, including the fear of failing. However, commercialization, like research and innovation, is only an enabler, and will not be sufficient to achieve the impact to the patients and population that we desire. To be able to improve the practice, we will need to leverage on innovations to change the system/workflow/culture – this is what disruptive innovation means.

I will describe the why, what, and how of NUHS’s Practice Changing Innovations (PCI) program, with the aim of deploying at least 5 innovations to improve patient and population care in the next 5 years. Ultimately, innovations are enablers, which will free us to focus on CARE and COMMUNICATION!
Lawrence Ho